A Systematic Literature Review of the Economic and Healthcare Resource Utilization Burden of Relapsed/Refractory Follicular Lymphoma
Bijal Shah,
Mei Xue (),
Wesley Furnback,
Erlene K. Seymour,
Jin Kim,
Po-Ya Chuang,
Madeline Dec and
Keri Yang
Additional contact information
Bijal Shah: Moffitt Cancer Center
Mei Xue: BeiGene
Wesley Furnback: Real Chemistry, Inc
Erlene K. Seymour: BeiGene
Jin Kim: Real Chemistry, Inc
Po-Ya Chuang: Real Chemistry, Inc
Madeline Dec: Real Chemistry, Inc
Keri Yang: BeiGene
PharmacoEconomics - Open, 2025, vol. 9, issue 4, No 3, 570 pages
Abstract:
Abstract Objective To quantify the economic or healthcare resource utilization (HCRU) burden and examine the value of interventions for relapsed or refractory (R/R) follicular lymphoma (FL). Methods The PubMed and Embase databases were searched for full-text studies and conference abstracts published between 1 January 2019 and 31 December 2023 that reported either the economic or HCRU burden of R/R FL or reported the results of health economic models assessing interventions for R/R FL. A supplemental manual search was also undertaken to identify conference abstracts that may not have been indexed in the primary databases. A data extraction sheet was used to develop evidence tables. Results A total of 30 records were included spanning 11 retrospective or prospective studies, 11 cost-effectiveness evaluations, and 8 other economic models. Costs and HCRU generally tended to increase as the line of therapy increased, reaching over US$400,000 annually in later lines. Costs associated with recently approved chimeric antigen receptor T-cell therapy (CAR-T) ranged from US$450,000 to over US$700,000 per patient. Economic models evaluating novel therapies, such as CAR-T, tazemetostat, and mosunetuzumab, estimated they would generally be cost-effective and have minimal budget impact or cost-savings. However, these models noted considerable assumptions regarding treatment duration and discontinuation. Real-world costs and resource use for newly approved therapies including CAR-Ts and bispecifics were limited. Conclusions The burden of R/R FL is substantial and increases as patients progress. Considerable gaps exist for the real-world impact of novel therapies, including CAR-Ts and bispecifics, on the economic burden and will need to be studied to properly assess their value.
Date: 2025
References: Add references at CitEc
Citations:
Downloads: (external link)
http://link.springer.com/10.1007/s41669-025-00577-z Abstract (text/html)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:9:y:2025:i:4:d:10.1007_s41669-025-00577-z
Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669
DOI: 10.1007/s41669-025-00577-z
Access Statistics for this article
PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell
More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().